35 related articles for article (PubMed ID: 28089983)
1. Efficacy and safety of abatacept in active primary Sjögren's syndrome: results of a phase III, randomised, placebo-controlled trial.
Baer AN; Gottenberg JE; St Clair EW; Sumida T; Takeuchi T; Seror R; Foulks G; Nys M; Mukherjee S; Wong R; Ray N; Bootsma H
Ann Rheum Dis; 2021 Mar; 80(3):339-348. PubMed ID: 33168545
[TBL] [Abstract][Full Text] [Related]
2. [Early prediction of severe COVID-19 in patients with Sjögren's syndrome].
Li JB; Lyu MN; Chi Q; Peng YL; Liu PC; Wu R
Beijing Da Xue Xue Bao Yi Xue Ban; 2023 Dec; 55(6):1007-1012. PubMed ID: 38101781
[TBL] [Abstract][Full Text] [Related]
3. Development and Application of the Placebo Response Model in Clinical Trials for Primary Sjögren's Syndrome.
Wang ZZ; Zheng QS; Liu HX; Li LJ
Front Immunol; 2021; 12():783246. PubMed ID: 34868062
[TBL] [Abstract][Full Text] [Related]
4. Can We Expect Any Effect of Rituximab on Fatigue in Primary Sjögren Syndrome?: A Systematic Review and Critical Appraisal.
Hermans AM; Vulsteke JB; Lenaerts J; De Langhe E
J Clin Rheumatol; 2021 Dec; 27(8):e510-e515. PubMed ID: 31804258
[TBL] [Abstract][Full Text] [Related]
5. Arthritis in primary Sjögren's syndrome: Characteristics, outcome and treatment from French multicenter retrospective study.
Mirouse A; Seror R; Vicaut E; Mariette X; Dougados M; Fauchais AL; Deroux A; Dellal A; Costedoat-Chalumeau N; Denis G; Sellam J; Arlet JB; Lavigne C; Urbanski G; Fischer-Dumont D; Diallo A; Fain O; Mékinian A;
Autoimmun Rev; 2019 Jan; 18(1):9-14. PubMed ID: 30408585
[TBL] [Abstract][Full Text] [Related]
6. 14-3-3η Proteins as a Diagnostic Marker, Disease Activation Indicator, and Lymphoma Predictor in Patients with Primary Sjögren Syndrome.
Kor A; Yalçın M; Erten Ş; Maraş Y; Oğuz EF; Doğan İ; Atalar E; Başer S; Erel Ö
Arch Iran Med; 2023 Oct; 26(10):582-591. PubMed ID: 38310415
[TBL] [Abstract][Full Text] [Related]
7. Severe Headache in Primary Sjögren's Syndrome Responded to Rituximab.
Kudsi M; Haidar G; Hadid B; Roumieh E; Al-Sayed S
Eur J Case Rep Intern Med; 2023; 10(10):004051. PubMed ID: 37789982
[TBL] [Abstract][Full Text] [Related]
8. Methods of assessment of joint involvement in various systemic connective tissue diseases.
Kardas T; Wielosz E; Majdan M
Reumatologia; 2022; 60(1):53-62. PubMed ID: 35645418
[TBL] [Abstract][Full Text] [Related]
9. Use of Biologics in Sjögren's Syndrome.
Nocturne G; Cornec D; Seror R; Mariette X
Rheum Dis Clin North Am; 2016 Aug; 42(3):407-17. PubMed ID: 27431344
[TBL] [Abstract][Full Text] [Related]
10. Emerging drugs for primary Sjögren's syndrome.
Gandolfo S; De Vita S
Expert Opin Emerg Drugs; 2019 Jun; 24(2):121-132. PubMed ID: 31286787
[No Abstract] [Full Text] [Related]
11. Detailed Analysis of the Articular Domain in Patients with Primary Sjögren Syndrome.
Moerman RV; Arends S; Meiners PM; Vissink A; Spijkervet FK; Kroese FG; Brouwer E; Bootsma H
J Rheumatol; 2017 Mar; 44(3):292-296. PubMed ID: 28089983
[TBL] [Abstract][Full Text] [Related]
12. A phase II investigator-initiated pilot study with low-dose cyclosporine A for the treatment of articular involvement in primary Sjögren's syndrome.
Kedor C; Zernicke J; Hagemann A; Gamboa LM; Callhoff J; Burmester GR; Feist E
Clin Rheumatol; 2016 Sep; 35(9):2203-10. PubMed ID: 27470087
[TBL] [Abstract][Full Text] [Related]
13. Articular and Peripheral Nervous System Involvement Are Linked to the Long-Term Outcome in Primary Sjögren's Syndrome: The Relevance of Single Organ Manifestations Rather Than a Composite Score as Predictors.
Quartuccio L; Gandolfo S; Zabotti A; Zandonella Callegher S; Fabro C; De Vita S
Front Immunol; 2019; 10():1527. PubMed ID: 31354708
[No Abstract] [Full Text] [Related]
14. Abatacept treatment reduces disease activity in early primary Sjögren's syndrome (open-label proof of concept ASAP study).
Meiners PM; Vissink A; Kroese FG; Spijkervet FK; Smitt-Kamminga NS; Abdulahad WH; Bulthuis-Kuiper J; Brouwer E; Arends S; Bootsma H
Ann Rheum Dis; 2014 Jul; 73(7):1393-6. PubMed ID: 24473674
[TBL] [Abstract][Full Text] [Related]
15. Severe Health-Related Quality of Life Impairment in Active Primary Sjögren's Syndrome and Patient-Reported Outcomes: Data From a Large Therapeutic Trial.
Cornec D; Devauchelle-Pensec V; Mariette X; Jousse-Joulin S; Berthelot JM; Perdriger A; Puéchal X; Le Guern V; Sibilia J; Gottenberg JE; Chiche L; Hachulla E; Yves Hatron P; Goeb V; Hayem G; Morel J; Zarnitsky C; Dubost JJ; Saliou P; Pers JO; Seror R; Saraux A
Arthritis Care Res (Hoboken); 2017 Apr; 69(4):528-535. PubMed ID: 27390310
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
